Welcome to the e-CCO Library!

OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Vermeire1, J-F. Colombel2, B. G. Feagan3, W. J. Sandborn4, B. E. Sands2, S. Danese5, G. D’Haens6, R. Panaccione7, D. T. Rubin8, I. Shafran9, A. Parfionovas10, R. Rogers*10, R. A. Lirio10, E. V. LoftusJr11

Created: Friday, 22 February 2019, 9:41 AM
OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: Final results from the GEMINI LTS study
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Remo Panaccione
Created: Tuesday, 28 May 2019, 3:32 PM
Vedolizumab
Files: 1
OP26: Programmable probiotic local delivery of anti-TNF-α nanobody to alleviate DSS-induced colitis
Year: 2024
Source: ECCO'24 Stockholm
Authors: Kang, Guangbo
Created: Tuesday, 30 April 2024, 5:03 PM
OP26: Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
Year: 2021
Source: ECCO'21 Virtual
Authors: Schreiber , S.W.(1);Ferrante , M.(2);Panaccione , R.(3);Colombel , J.F.(4);Hisamatsu , T.(5);Lim , A.(6);Lindsay , J.O.(7);Rubin , D.T.(8);Sandborn , W.J.(9);Neimark , E.(10);Song , A.P.(10);Liao , X.(10);Feng , T.(10);Berg , S.(10);Wallace , K.(10);D’Haens , G.R.(11)
Created: Wednesday, 2 June 2021, 4:12 PM
OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s disease: Final results from the Phase 2 open-label extension study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Ferrante1, B.G. Feagan2, J. Panés3, F. Baert4, E. Louis5, O. Dewit6, A. Kaser7, W.R. Duan8, D. Gustafson9, X. Liao10, K. Wallace9, J. Kalabic11, G.R. D’Haens12

Created: Thursday, 30 January 2020, 10:12 AM
OP27: A Phase 1 Study Evaluating the Bioequivalence of the Proposed Commercial and Clinical Formulations of Etrasimod 2mg, and the Effect of Food on the Pharmacokinetics of the Proposed Commercial Formulation in Healthy Volunteers
Year: 2022
Source: ECCO'22
Authors: Lee, C.(1);Ramaiya, A.(1);Tang , Y.(1);Sapone, A.(2);Shan , K.(3);Randle, A.(4);Grundy, J.(1);
Created: Friday, 11 February 2022, 3:52 PM
OP27: Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCU
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cristina Rubín De Célix
Created: Friday, 14 July 2023, 2:22 PM
OP27: Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCU
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Rubín De Célix, C.(1)*;Martín de Carpi, J.(2);Pujol, G.(2);Palomino, L.(3);Velasco, M.(3);Martín-Masot, R.(4);Navas-López, V.M.(4);Ricart, E.(5);Casanova, M.J.(1);Rodríguez Martínez, A.(6);Leo, E.(7);Alcaraz, A.(8);Mañosa, M.(9);Hernández, V.(10);Fernández, R.(10);Sánchez, C.(11);Menchén, L.(12);Mesonero, F.(13);Barreiro-De Acosta, M.(14);Martinon, N.(15);Tejido Sandoval, C.(16);Rendo Vázquez, A.(17);Corsino, P.(18);Vicente, R.(18);Hernández-Camba, A.(19);Alberto Alonso, J.R.(20);Alonso-Abreu, I.(21);Castro Millán, A.M.(22);Peries Reverter, L.(23);Castro, B.(24);Fernández-Salgado, E.(25);Busto Cuiñas, M.M.(26);Benítez, J.M.(27);Madero, L.(28);Clemente, F.(29);Riestra, S.(30);Jiménez-Treviño, S.(31);Boscá, M.(32);Chaparro, M.(1);Gisbert, J.P.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP27: Has been withdrawn
Year: 2021
Source: ECCO'21 Virtual
Authors: Has been withdrawn
Created: Wednesday, 2 June 2021, 4:12 PM
OP27: High-dimensional mass cytometry reveals the immune cell landscape in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. van Unen1, N. Li1, T. Abdelaal2,3, Y. Kooy-Winkelaar1, L. Ouboter*1,4, G. Beyrend1, T. Höllt3,6, L. Mearin7, A. Witte8, H. Escher9, B. Lelieveldt10,11, A. van der Meulen - de Jong4, F. Koning1

Created: Friday, 22 February 2019, 9:41 AM
OP27: Oxalyl-CoA decarboxylase is a major and specific virulence factor for Adherent Invasive Escherichia coli
Year: 2024
Source: ECCO'24 Stockholm
Authors: Toumi, Eya
Created: Tuesday, 30 April 2024, 5:03 PM
OP28 Gene expression (GE) values in a phase 2 trial of mirikizumab in ulcerative colitis (UC) correlate better with histopathology (HP) than endoscopy (EN) and Mayo scores
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Steere1, K. GOTTLIEB1, J. Schmitz2, R. Higgs1, B. Jia1, C. Milch1, J. Tuttle3, V. Krishnan1, R. Belin1, W. Reinisch4

Created: Thursday, 30 January 2020, 10:12 AM
OP28: A randomized placebo controlled clinical trial with 5-hydroxytryptophan in patients with quiescent Inflammatory Bowel Disease and fatigue (Trp-IBD)
Year: 2022
Source: ECCO'22
Authors: Truyens, M.(1,2,3);Lobaton, T.(1,3);Peeters, A.(1);Ferrante, M.(4,5);Vermeire, S.(4,5);Bossuyt, P.(6);Pouillon, L.(6);Dewint, P.(7,8);Cremer, A.(9);Peeters, H.(10);Lambrecht, G.(11);Louis, E.(12);Rahier, J.F.(13);Dewit, O.(14);Muls, V.(15);Holvoet, T.(1,16);Vandermeulen, L.(17);Gonzales, G.B.(2,3,18);Laukens, D.(2,3);De Vos, M.(3);
Created: Friday, 11 February 2022, 3:52 PM
OP28: Children and young adults with inflammatory bowel disease have an increased incidence and risk of developing mental health conditions: a UK population-based cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cooney, R.(1)*;Tang, D.(2);Barrett, K.(3);Russell, R.K.(4);
Created: Friday, 14 July 2023, 10:43 AM